Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic
events in patients undergoing Percutaneous Coronary Intervention (PCI). However, oral administration
of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor
is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate
antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition
and very short plasma half-life it allows effective and controllable periprocedural platelet inhibition.
It could reduce short-term ischemic events in large randomized clinical trials. The present article reviews
the available evidence and application on cangrelor use in clinical practice.
Keywords: Cangrelor, P2Y12-receptor inhibitors, platelet inhibition, coronary artery disease, acute coronary syndrome, percutaneous
Rights & PermissionsPrintExport